871例人乳头瘤病毒16/18阳性者阴道镜活检结果的回顾性分析

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective To retrospectively analyze the results of ThinPrep cytologic test (TCT) and colposcopy biopsy of human papillomavirus (HPV) 16/18 positive patients,and to explore the value of using HPV16/18 partial typing in the early diagnosis of cervical lesions.Methods Altogether 871 cases of HPV16/18 positive patients who were referred for colposcopy biopsy in the Department of Obstetrics and Gynecology,the First Affiliated Hospital of Nanchang University from January 2016 to January 2018 were collected,and their age,TCT,HPV and the pathological results were collected for statistical analysis.Results Of all the 871 patients included in this study,469 cases (53.8%) were cervical inflammation,111 cases (12.7%) were cervical intraepithelial neoplasia 1 (CIN1),84 cases (9.6%) were CIN2,124 cases(14.2%) were CIN3,and 83 cases (9.5%) were cervical cancer.The HPV16/18 positive patients were subgrouped into 21-30,>30-40,>40-50,and >50 years old,and the proportions of CIN2+lesions were 19.1% (31/162) and 28.4% (64/225),39.1% (109/279),42.4% (87/205),respectively.Among the HPV16/18 positive and menopausal patients,the detection rate of CIN2+lesions was higher than that of non-menopausal patients (40.4% vs.30.7%),and the difference was statistically significant (χ2=7.31,P<0.01).Conclusion The detection rate of CIN2+lesions in HPV16/18 positive patients is about 33.4%,and with the increase of age,the detection rate of CIN2+tends to increase gradually.The immediate transfer of patients to colposcopy whose HPV16/18 shows positive is very helpful to the early detection of cervical lesions.

Key words： font-size: 16px Human papillomavirus;Cervical intraepithelial lesion;Colposcopy;Biopsy;Cervical cancer screening;ThinPrep cytologic test')" href="#">text-align: justify;">Human papillomavirus;Cervical intraepithelial lesion;Colposcopy;Biopsy;Cervical cancer screening;ThinPrep cytologic test

PACS:

Fund:

	Service

	E-mail this article Human papillomavirus;Cervical intraepithelial lesion;Colposcopy;Biopsy;Cervical cancer screening;ThinPrep cytologic test”. Please open it by linking:https://www.dangdaiyiyao.com/EN/abstract/abstract13500.shtml" name="neirong">
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I32/9

[1]	吉洁，马志君，曹振东，等.HPV16/18 感染与宫颈鳞癌VEGF-C、VEGFR-3 表达的关系[J].中华保健医学杂志，2019，21（1）：60-62.
[2]	王春兰，陆燕，仲玉英，等.HPV16型感染者宫颈组织p16、Ki-67 表达及早期干预的对比研究[J].实用妇科内分泌电子杂志，2019，6（16）：95-97，170.
[3]	陈丽梅.宫颈癌筛查技术发展及最新筛查指南[J].上海医药，2018，39（1）：3-7，46.
[4]	周红娣，金福明，沈铿.2016年美国妇产科医师学会推荐的宫颈癌筛查及预防指南的解读[J].现代妇产科进展，2016，25（6）：401-405，410.
[5]	Huh WK，Auh KA，Chelmow D，et al.Use of primary high-risk human papillomavirus testing for cervical cancer screening：interim clinical guidance[J].Gynecol Oncol，2015，136（2）：178-182.
[6]	美国预防服务工作组.美国预防服务工作组宫颈癌筛查指南[J].中华预防医学杂志，2019，53（3）：246.
[7]	中国优生科学协会阴道镜和宫颈病理学分会专家委员会.中国子宫颈癌筛查及异常管理相关问题专家共识（一）[J].中国妇产科临床杂志，2017，18（2）：190-192.
[8]	中国优生科学协会阴道镜和宫颈病理学分会(CSCCP)专家委员会.中国子宫颈癌筛查及异常管理相关问题专家共识（二）[J].中国妇产科临床杂志，2017，18（3）：286-288.
[9]	Wright TC，Stoler MH，B ehrens CM，et al.Primary cervical cancer screening with human papillomavirus：End of study results from the ATHENA study using HPV as the first-line screening test[J].Gynecol Oncol，2015，136（2）：189-197.
[10]	Stoler MH，Wright TC，Parvu V，et al.The Onclarity Human Papillomavirus Trial：Design，methods，and baseline results[J].Gynecol Oncol，2018，149（3）：498-505.
[11]	Huh WK，Williams E，Huang J，et al.Cost effectiveness of human papillomavirus 16/18 genotyping in cervical cancer screening[J].Appl Health Econ Health Policy，2015，13（1）：95-107.
[12]	Arbyn M，Rezhake R，Yuill S，et al.Triage of HPV-positive women in Norway using cytology，HPV16/18 genotyping and HPV persistence[J].Brit J Cancer，2020，122(11)：1577-1579.
[13]	Kares S，Veijalainen O，Kholová I，et al.HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer：the value of HPV16 and HPV18 genotyping?[J].APMIS，2019，127（11）：710-716.
[14]	韩钦，郭红燕，耿力.宫颈癌机会性筛查人群中高危型HPV感染状况及其与宫颈病变关系的研究[J].实用妇产科杂志，2018，34（3）：194-197.
[15]	张健欣，郑婷萍，刘军，等.单纯HPV16/18阳性行阴道镜检查有可疑病变患者的子宫颈组织病理检查结果分析[J].中华妇产科杂志，2017，52（7）：467-472.
[16]	伏晨阳，成燕.评价HPV16/18阳性直接转诊阴道镜在本地宫颈癌筛查中的可行性探讨[J].吉林医学，2019，40（6）：1310-1311.
[17]	Wu Q，Zhao X，Fu Y，et al.A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11，064 Chinese women[J].Cancer Med，2017，6（5）：1091-1101.
[18]	Rodríguez AC，Schiffman M，Herrero R，et al.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections[J].J Natl Cancer Inst，2008，100（7）：513-517.
[19]	赵昀，魏丽惠.CSCCP 关于中国宫颈癌筛查及异常管理相关问题专家共识解读[J].实用妇产科杂志，2018，34（2）：101-104.
[20]	原新丽，吴祁生，张火兵，等.液基细胞学检查在不同年龄段女性子宫颈癌前病变筛查中的现状研究[J].标记免疫分析与临床，2020，27（1）：27-31.
[21]	黄燕明，王燕，阳艳，等.宫颈细胞学正常的高危HPV感染妇女病理结局分析[J].现代妇产科进展，2017，26（2）：143-144，148.